尊龙凯时·(中国区)人生就是搏!

    EN
    ×
    EN
    • 业务咨询

      中国:

      Email: marketing@vi-home.com

      业务咨询专线:400-780-8018

      (仅限服务咨询,其他事宜请拨打川沙总部电话)

      川沙总部电话: +86 (21) 5859-1500

      海外:

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com

    在线留言×
    点击切换

    搜索结果包含 solid 的内容

    Jul 02,2025
    MCL1抑制剂在多种实体瘤和血液肿瘤模型中显示抗肿瘤效果,本研究中药效实验通过尊龙凯时进行
    CDX studies were performed at Shanghai Medicilon (OS-RC-2). All studies were performed in accordance with animal research guidelines from the Shanghai Medicilon Inc.
    查看更多
    MCL1抑制剂在多种实体瘤和血液肿瘤模型中显示抗肿瘤效果,本研究中药效实验通过尊龙凯时进行
    Jul 06,2023
    PTX-HSN是一种高效纳米系统,具有较高耐受剂量,可将PTX递送至卵巢癌并增强主动肿瘤靶向性。此研究中所有体内实验均通过尊龙凯时进行
    Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,
    查看更多
    PTX-HSN是一种高效纳米系统,具有较高耐受剂量,可将PTX递送至卵巢癌并增强主动肿瘤靶向性。此研究中所有体内实验均通过尊龙凯时进行
    Jun 28,2023
    CAR-T疗法主要针对白血病与恶性淋巴瘤,本研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过尊龙凯时进行
    Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR i
    查看更多
    CAR-T疗法主要针对白血病与恶性淋巴瘤,本研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过尊龙凯时进行
    ×
    搜索验证
    点击切换